Scholarlink

<p>Cellular neurothekeoma is an uncommon dermal neoplasm that frequently overlaps histologically with fibrohistiocytic and melanocytic tumors, particularly in superficial or limited biopsies. MiTF immunohistochemistry is commonly used for diagnostic support but shows inconsistent sensitivity with variable and often focal expression patterns, which can complicate interpretation. Cyclin D1 is a widely available nuclear marker expressed in some related fibrohistiocytic tumors, but its performance in cellular neurothekeoma has not been studied. Eleven cellular neurothekeomas diagnosed over a 7-year period were identified. Immunohistochemistry for cyclin D1 and MiTF was performed on formalin-fixed, paraffin-embedded tissue. Slides were independently scored using the blue–brown color H-score method, including assessment of overall H-scores and the proportion of tumor nuclei staining at ≥ 2+ intensity. Cyclin D1 showed consistently strong nuclear expression in all cases (11/11, 100%), with a median H-score of 205 (IQR 200–222.5), compared with 40 for MiTF (IQR 27.5–115) (<i>p</i> &lt; 0.001). Strong (≥ 2+) nuclear staining was present in a median of 90% of tumor cells with cyclin D1 (IQR 82.5–100), versus 10% with microphthalmia transcription factor (IQR 0–35) (<i>p</i> &lt; 0.001). MiTF was&#xa0;interpreted as positive in fewer than half of cases (5/11, 45%). Cyclin D1 demonstrated uniform, strong nuclear expression and superior sensitivity compared with MiTF, supporting its use as a sensitive and dependable immunohistochemical marker for cellular neurothekeoma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cyclin D1 demonstrates superior sensitivity and consistent nuclear expression compared with MiTF in cellular neurothekeoma

  • 期刊论文

  • 发表日期：

    2026年2月24日

查看全文
  • Jeffrey A. Sanford,
  • Damien Abreu,
  • Jaroslaw J. Jedrych

摘要

Cellular neurothekeoma is an uncommon dermal neoplasm that frequently overlaps histologically with fibrohistiocytic and melanocytic tumors, particularly in superficial or limited biopsies. MiTF immunohistochemistry is commonly used for diagnostic support but shows inconsistent sensitivity with variable and often focal expression patterns, which can complicate interpretation. Cyclin D1 is a widely available nuclear marker expressed in some related fibrohistiocytic tumors, but its performance in cellular neurothekeoma has not been studied. Eleven cellular neurothekeomas diagnosed over a 7-year period were identified. Immunohistochemistry for cyclin D1 and MiTF was performed on formalin-fixed, paraffin-embedded tissue. Slides were independently scored using the blue–brown color H-score method, including assessment of overall H-scores and the proportion of tumor nuclei staining at ≥ 2+ intensity. Cyclin D1 showed consistently strong nuclear expression in all cases (11/11, 100%), with a median H-score of 205 (IQR 200–222.5), compared with 40 for MiTF (IQR 27.5–115) (p < 0.001). Strong (≥ 2+) nuclear staining was present in a median of 90% of tumor cells with cyclin D1 (IQR 82.5–100), versus 10% with microphthalmia transcription factor (IQR 0–35) (p < 0.001). MiTF was interpreted as positive in fewer than half of cases (5/11, 45%). Cyclin D1 demonstrated uniform, strong nuclear expression and superior sensitivity compared with MiTF, supporting its use as a sensitive and dependable immunohistochemical marker for cellular neurothekeoma.